Form 4: Xeris Biopharma Director Plans Future Stock Sale

A director at Xeris Biopharma Holdings, Inc. has filed a plan to sell 135,400 shares of common stock on December 19, 2025, at an average price of $7.2158.

Summary

• John Johnson, a Director of Xeris Biopharma Holdings, Inc. (XERS), has filed a Statement of Changes in Beneficial Ownership (Form 4).
• The filing indicates a planned sale of 135,400 shares of Common Stock on December 19, 2025.
• The transaction is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), indicating a pre-arranged trading plan.
• The shares are planned to be sold at a weighted average price of $7.2158 per share, with individual transactions ranging from $7.200 to $7.275.
• Following this planned transaction, John Johnson will beneficially own 698,083 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The planned sale by a director, while under a Rule 10b5-1 plan (which often indicates personal financial planning rather than market timing), still represents a reduction in insider ownership. This is a neutral to slightly negative signal, as it doesn't reflect increased confidence, but the pre-planned nature mitigates strong negative interpretation.

Negatives

• A planned sale by a director, even under a Rule 10b5-1 plan, represents a reduction in insider holdings, which can sometimes be interpreted as a slightly negative signal regarding future prospects or valuation.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the planned insider transaction.

Stakeholder Impact

• Shareholders may interpret the planned insider sale as a signal, potentially influencing market sentiment, although the Rule 10b5-1 plan suggests it's a pre-scheduled event rather than a reaction to immediate company news.

Key Dates

Recommendation

The planned sale by a director, even under a Rule 10b5-1 plan, is a data point indicating a reduction in insider holdings. While such plans are often for personal financial management and not necessarily a reflection of the company's immediate prospects, it does not signal increased confidence. Investors should monitor future insider activity and company performance, but this single planned transaction does not warrant a change from a 'hold' position without further context.

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Stock Sale, Director Transaction, Rule 10b5-1